Pfizer’s new drug applications for tafamidis accepted for filing by FDA

“Pfizer Inc’s PFE, -1.43% two new drug applications for tafamidis for the treatment of a fatal heart condition have been accepted for filing by the U.S. Food and Drug Administration, the company announced Monday” writes Sarah Toy for One of those forms, tafamidis meglumine, was granted priority review and has a July 2019 Prescription Drug User Fee Act target date for FDA review, the company said.Pfizer submitted the NDAs based on two forms of the drug for treatment of transthyretin amyloid cardiomyopathy, a fatal condition where a transport protein in the blood misfolds and results in a build-up of amyloid fibrils in the heart, the company said.

Related posts